Clinical phase II and III studies of an AS03‐adjuvanted H5N1 influenza vaccine produced in an EB66(®) cell culture platform

BACKGROUND: We have developed an AS03‐adjuvanted H5N1 influenza vaccine produced in an EB66(®) cell culture platform (KD‐295). OBJECTIVES: In accordance with Japanese guidelines for development of pandemic prototype vaccines, the phase II study was conducted in a double‐blind, randomized, parallel‐g...

Descripción completa

Detalles Bibliográficos
Autores principales: Endo, Masafumi, Tanishima, Mitsuyoshi, Ibaragi, Kayo, Hayashida, Kenshi, Fukuda, Tadashi, Tanabe, Tetsuro, Naruse, Takeshi, Kino, Yoichiro, Ueda, Kohji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431644/
https://www.ncbi.nlm.nih.gov/pubmed/32579785
http://dx.doi.org/10.1111/irv.12755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431644/
https://www.ncbi.nlm.nih.gov/pubmed/32579785
http://dx.doi.org/10.1111/irv.12755

Ejemplares similares